|Awarded On||August 18, 2021|
|Title||Synergy between epigenetic reprogramming and Wnt inhibition to enhance neuroendocrine tumor radionuclide therapy|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||The University of Texas Health Science Center at Houston|
|Principal Investigator/Program Director||Jeffrey Frost|
|Cancer Sites||Pancreas, Small Intestine, Stomach|
Gastero-entero-pancreatic NETs (GEP-NETs) are slow growing tumors that are often diagnosed at late stage, making them difficult to treat. A current primary therapy for GEP-NETs is use of activators of Somatostatin receptor 2 (Sstr2), which suppress hormonal secretion and tumor cell proliferation in inoperable tumors. Sstr2 is a peptide receptor that is often highly expressed in GEP-NETs. A promising, recently approved therapy for GEP-NETs makes use of radioactive forms of Sstr2 activators (called PRRT), which deliver radiation specifically to the tumors. However, this therapy often is not curative because of residual, untargeted tumor, and is limited to patients with high-level expression of...